FXR agonist 13

FXR agonist 13 is a selective, orally active, potent FXR agonist (EC50 = 0.097 μM) and has favorable hepatic microsomal metabolic stability. FXR agonist 13 exhibits moderate affinity for FXR-LBD upon direct binding (KD = 14.74 μM) . FXR agonist 13 displays good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. FXR agonist 13 can be used for the study of metabolic-associated steatohepatitis (MASH) [1].

Product Specifications

Target

FXR

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C(C1=CC=C(C=C1)CN(C(C2=NN(C3=C2C=CC=C3Cl)CCC(F)(F)F)=O)CC4=CC(F)=CC=C4)O

Molecular Formula

C26H20ClF4N3O3

Molecular Weight

533.90

References & Citations

[1]Shi DY, et al. Discovery of novel potent indazole-based FXR agonists via scaffold hopping for MASH treatment. Eur J Med Chem. 2026 Jan 5;301:118203.